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Abstract 
Emerging evidence suggests that the three
tyrosine kinase inhibitors currently approved
for  the  treatment  of  patients  with  chronic
myelogenous  leukemia  (CML)  –  imatinib,
dasatinib, and nilotinib – have potential car-
diotoxic  effects.  The  mechanisms  behind
these events, and the relations between them,
are  largely  unclear.  For  example,  relative  to
dasatinib  and  nilotinib,  severe  congestive
heart failure and left ventricular dysfunction
are  rare  but  prominent  with  imatinib  treat-
ment, particularly in patients receiving higher
doses (>600 mg/day). In comparison with ima-
tinib, prolongation of the QT interval is rela-
tively common in patients treated with either
dasatinib or nilotinib. In contrast to nilotinib,
pericardial effusions are observed with both
imatinib  and  dasatinib.  It  is  suggested  that
these data, an evaluation of cardiac status, use
of concomitant medications, and potential risk
factors should be considered in the manage-
ment of CML. 
Introduction
BCR-ABL tyrosine kinase is a key molecule
responsible for the pathophysiology of chronic
myelogenous  leukemia  (CML).  Tyrosine
kinase inhibitors (TKIs) directed against BCR-
ABL are currently the cornerstone of treatment
for  patients  with  CML.  Imatinib  (Gleevec
®;
Novartis  Pharmaceuticals  Corporation,  New
Jersey,  USA)  was  the  first  TKI  approved  for
CML. Imatinib has marked response and sur-
vival benefits over interferon-α plus low-dose
cytarabine  and  is  presently  the  only  TKI
licensed  for  first-line  treatment.
1,2 However,
despite  the  remarkable  success  of  imatinib,
many patients discontinue treatment because
of either resistance or intolerance to this drug. 
In the pivotal phase III IRIS (International
Randomized Study of Interferon and STI571)
trial, primary resistance was observed in 24%
of patients, and secondary resistance present-
ed as relapse in 17% of patients and disease
progression in 7% after 4.5 years.
2 After six
years of follow-up, 34% of patients had discon-
tinued  imatinib  treatment,  mostly  (14%)
because of an unsatisfactory therapeutic effect
(defined as lack of efficacy/progression), but a
number of patients (5%) also stopped receiv-
ing the drug as a result of adverse events (AEs)
or abnormal laboratory values.
3 Further treat-
ment options therefore continue to be devel-
oped.
Second-line  choices  for  treatment  include
increasing the dose of imatinib, or changing
therapy to dasatinib [Sprycel
®; Bristol-Myers
Squibb Co. (BMS), New York, USA] or nilo-
tinib  (Tasigna
®;  Novartis  Pharmaceuticals
Corp.,  New  Jersey,  USA).  Newer  agents  for
imatinib failures are still under clinical devel-
opment.
4Dasatinib potently inhibits BCR-ABL.
5
Compared  with  imatinib,  dasatinib  has  325-
fold greater activity against native BCR-ABL.
6
Furthermore,  dasatinib  inhibits  all  imatinib-
resistant  mutations  of  this  molecule  (key
mediators of imatinib resistance) except the
T315l mutant, which is resistant to all current-
ly  available  TKIs.
6-8 It  is,  however,  relatively
insensitive to the F317L mutation.
9
Dasatinib  was  originally  approved  at  the
dosage  of  70  mg  twice  daily,  following  data
from the START (the SRC/ABL Tyrosine Kinase
Inhibition  Activity:  Research  Trials  of
Dasatinib)  program  of  clinical  studies.
10-12 In
November  2007,  the  label  for  dasatinib  was
changed to include updated dosing informa-
tion, safety information from more than 2,100
patients, and data from a randomized compar-
ison  with  high-dose  imatinib.
13 The  recom-
mended starting dose for patients with chron-
ic phase (CP) CML is now 100 mg once daily.
The  starting  dose  for  advanced  disease
remains 70 mg twice daily. 
Nilotinib  (an  analog  of  imatinib)  is  also
active against all imatinib-resistant BCR-ABL
mutations except T315l.
14 However, nilotinib is
relatively inactive against common mutations
in the ATP-binding P-loop domain,
4 and those
at the F359 residue in the catalytic domain, of
BCR-ABL.
6 Patients harboring such mutations
at  baseline  do  not  respond  to  nilotinib  and
progress  quickly  during  treatment.  Further  -
more, patients who do not have these muta-
tions at baseline may eventually develop them
when resistance to imatinib occurs.
15 Nilotinib
has  recently  been  approved  by  the  FDA  for
treating  imatinib-resistant  and  -intolerant
patients with CP or accelerated phase CML, but
not those suffering from blast crisis. 
TKIs  share  a  number  of  common  adverse
effects  (AE),  including  neutropenia  and
thrombocytopenia. Cardiotoxicities of the TKIs
have become a clinical concern. This review
provides an overview of common AEs and car-
diotoxicities associated with these TKIs.
Common adverse events 
associated with tyrosine kinase
inhibitors
A number of AEs are associated with TKIs.
The most common ones are hematologic. In
the  IRIS  study,  anemia,  neutropenia,  and
thrombocytopenia  (all  grades)  were  each
reported by 45-61% of patients receiving ima-
tinib.
1 Grade  3-4  anemia,  neutropenia,  and
thrombocytopenia were observed in 3%, 14%,
and 8% of patients, respectively. The updated
dasatinib label includes data from the START-R
trial, a comparison of dasatinib 70 mg twice
daily with high-dose imatinib (800 mg/day) in
patients with CP CML resistant to standard-
dose imatinib.
13,16 In this study, the incidences
of grade 3-4 thrombocytopenia and neutrope-
nia for high-dose imatinib were 14% and 39%,
respectively. The START-R study also showed
that  dasatinib  has  significant  response  and
progression-free  survival  benefits  compared
with high-dose imatinib, and that significantly
more patients discontinue high-dose imatinib
than dasatinib.
16
The 100 mg once daily dose for dasatinib in
patients with CP CML was approved as a result
of  data  from  a  phase  III  dose  modification
study.
17 Shah and colleagues compared dasa-
tinib 100 mg once daily, 50 mg twice daily, 140
mg once daily, and 70 mg twice daily doses in
CP  CML.  In  this  study,  response  rates  were
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similar between doses, and overall efficacy was
equivalent between the 70 mg twice daily and
100 mg once daily regimens. In the 100 mg
once  daily  dose  there  was  significantly  less
grade  3-4  thrombocytopenia  (22%;  p=0.004)
compared  with  the  70  mg  twice  daily  dose
(37%).  Grade  3-4  anemia,  leukopenia,  and
neutropenia were observed in 10%, 16% and
33% of patients, respectively. The 100 mg once
daily dose was also associated with the lowest
frequencies  of  treatment  discontinuation
(overall: 16% vs. 23%; toxicity alone: 4% vs.
11%, respectively). 
For nilotinib, the incidence rates of grade 3-
4  thrombocytopenia  (28%),  neutropenia
(28%), and anemia (8%) at the recommended
dose (800 mg/day) in patients with CP CML
appear to be similar to those for dasatinib 100
mg once daily.
17,18
The incidences of non-hematologic AEs are
much lower than those for hematologic events
for all TKIs, and are broadly similar between
TKIs  at  their  current  recommended  doses.
Cutaneous toxicity is more common for TKIs
against receptor tyrosine kinases.
19
Cardiotoxicities observed in
chronic myeloid leukemia
Current evidence suggests that TKIs have
potential  cardiotoxic  effects.  Cardiac  AEs
reported include palpitations, arrhythmia, QT
prolongation, pericardial effusions, myocardial
ischemia, myocardial infarction, and conges-
tive heart failure (CHF). All of the clinically
available BCR-ABL inhibitors report the poten-
tial for cardiotoxicity in their respective pack-
age inserts (Table 1).
13,18,20
Imatinib 
Although rare, severe CHF and left ventric-
ular  dysfunction  have  been  reported  during
imatinib treatment, especially in patients with
risk factors or comorbidities. In the IRIS trial,
this  was  observed  in  0.7%  of  patients.
1,2,20
Cardiotoxicity associated with high-dose ima-
tinib  was  not  reported  during  the  START-R
study.
16 In smaller studies of high-dose ima-
tinib,  existing  CHF  was  exacerbated  in  one
study  (6%  of  patients),  and  was  related  to
mortality in another (4% of patients).
21,22
In  a  large  review  of  patients  enrolled  in
imatinib clinical studies (n=1,276), 1.8% of
patients had symptoms suggestive of systolic
heart failure. Most had risk factors for cardiac
failure. In total, 0.6% of patients had cardiac
events attributed to imatinib treatment. The
authors  concluded  that  CHF  is  rare  during
imatinib  treatment.
23 A  similar  incidence  of
CHF (1%) was reported in a nine-year retro-
spective  review  at  a  single  institution.
24
Reports of smaller studies also confirm that
cardiac failure is a rare feature of imatinib
therapy.
25,26
The  mechanism  underlying  imatinib-
induced cardiac failure is currently unclear. In
an in vitro study, physiological concentrations
of imatinib significantly and adversely affect-
ed mitochondrial membrane potential, apopto-
sis, cell viability, and cellular ultrastructure.
27
This cardiotoxic effect may be linked to inhi-
bition of BCR-ABL. Imatinib was reported to
cause  stress-induced  and  dose-dependent
mitochondrial changes in murine ventricular
myocytes, which was reduced by re-engineer-
ing the imatinib molecule such that BCR-ABL
inhibition was hampered.
28,29 Nonetheless, the
re-engineered molecule may have had altered
activities  besides  reduced  BCR-ABL  inhibi-
tion.
A second cardiac AE associated with ima-
tinib therapy is fluid retention manifesting as
pericardial effusion. Grade 3-4 fluid retention
reactions,  which  included  pericardial  effu-
sions, were reported in 2% of patients in the
IRIS study and in 6% of all other CML clinical
studies.
20Frank pericarditis has been observed
in <0.1% of patients receiving imatinib (all
indications).
20 Other  cardiac  AEs  include
tachycardia, hypertension, hypotension, flush-
ing,  and  peripheral  coldness,  were  each
reported in 0.1-1.0% of patients.
20
Precautions and general guidelines for dose
adjustment  for  cardiac  AEs  associated  with
imatinib treatment are included in the pre-
scribing information and have been summa-
rized in Table 2. CML patients with existing
cardiac disease or cardiac risk factors should
be  monitored  and  treated  accordingly.
20,23
Patients should also be weighed regularly and
monitored  for  signs  and  symptoms  of  fluid
retention. Unexpected weight gain should be
investigated  carefully,  and  treated  appropri-
ately.
20,30 Significant  fluid  retention  (local  or
general) can usually be managed by interrupt-
ing imatinib treatment and using diuretics or
other supportive care.
20 In severe cases of fluid
retention, imatinib should be withheld until
this is resolved.
Nilotinib 
Nilotinib  can  cause  QT  prolongation  and
sudden death and carries a black box warning
for these side effects.
18 Nilotinib prolongs the
QT  interval  in  a  concentration-dependent
manner, and the common AEs occurred in 1-
10% of all patients in clinical trials.
18 In a study
in healthy volunteers, nilotinib was associated
with a maximum mean QT interval increase of
18  ms  (adjusted  for  placebo).
18 In  imatinib-
resistant patients with CML, nilotinib caused a
maximum  mean  QT  change  of  10  ms  from
baseline; QT increase >60 ms and QT >500 ms
associated with nilotinib were reported in 2.1%
and  <1%  of  patients,  respectively.  Sudden
deaths were reported in 0.6% of patients in a
clinical study, and at a similar frequency in an
expanded access study. The early occurrences
of some of these deaths relative to the start of
nilotinib  treatment  suggest  that  ventricular
repolarization may have contributed to their
occurrence.
18
Another common cardiac AE associated with
nilotinib  therapy  is  myocardial  ischemia.  In
the pivotal phase II study, it was reported in 7%
(21/321)  of  patients  with  CP  CML  receiving
nilotinib  as  second-line  treatment.
31
Uncommon  cardiac  events  (0.1-1%  of  all
patients in clinical trials) include cardiac fail-
ure, angina pectoris, atrial fibrillation, pericar-
dial  effusion,  coronary  artery  disease,  car-
diomegaly, cardiac murmur, and bradycardia.
Rare events (of uncertain frequency) include
myocardial infarction, ventricular dysfunction,
pericarditis, cardiac flutter, and extrasystoles.
18
The mechanisms underlying these AEs are
still unclear. In a manner similar to imatinib,
nilotinib  was  found  to  decrease  the  cellular
viability  of  rat  cardiomyocytes  cultured  in
vitro, although the integrity of the mitochondr-
ial  membrane  potential  was  unaffected.
27
However,  nilotinib  has  also  been  found  to
inhibit  human  ether-a-go-go  related  gene
(hERG) potassium  currents  with  an  IC50 of 
0.66 ʼM. This concentration is approximately
one-tenth  the  expected  Cmax  for  this  com-
pound,  well  within  therapeutic  levels.  This
mechanism  is  likely  to  underlie  nilotinib-
induced QT prolongation. Inhibition of hERG
channels is established as a cause of QT pro-
longation for a number of compounds, and is a
significant barrier in the development of new
drugs.
32 Indeed, the phase II development of
the aurora kinase inhibitor MK-0457 (VX-680)
was recently suspended, pending a full analy-
sis of all efficacy and safety data. The decision
was based on preliminary safety data, in which
QT prolongation was observed in one patient.
33
The potential for QT prolongation and sud-
den death associated with nilotinib, although
rare, necessitates vigilant monitoring. In par-
ticular, ECGs should be performed at baseline,
seven days after initiation of treatment, peri-
odically  throughout  therapy,  and  following
dose adjustments. Electrolyte levels should be
monitored  periodically  throughout  therapy.
Nilotinib is contraindicated for patients with
hypokalemia,  hypomagenesmia  or  long  QT
syndrome.
18 The nilotinib prescribing informa-
tion recommends dose adjustments for QT pro-
longation, presented in Table 2.
Dasatinib 
The events of dasatinib-induced QT prolon-
gation are rare although a warning for such a
possible event is given. In single-arm studies
of dasatinib, nine patients (1%) had QT pro-
longation reported as an AE.
13 The mean QTArticle
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interval  increased  by  3-6  ms  (Fridericia’s
method); this increase was not clinically rele-
vant.
34 In  total,  <1%  of  patients  had  a  QT
increase to >500 ms. In contrast with nilotinib,
the IC50for dasatinib for the inhibition of hERG
currents (14.3 ʼM) is 100 times the expected
Cmax for this drug.
27 This may explain why QT
prolongation is more clinically prominent for
nilotinib than it is for dasatinib. 
Common cardiac AEs (observed in 1 – <10%
of  all  patients  in  clinical  trials)  include
arrhythmia and palpitations. Severe pericar-
dial effusions have been reported in 1% of all
patients in all clinical studies, and the pre-
scribing information for dasatinib includes a
warning for this toxicity.
13Severe CHF has also
been reported in 1% of all patients.
13 In single-
arm studies, CHF or ventricular dysfunction
occurred  in  4%  (20/911)  of  patients.
34
However, in the dose optimization study, dasa-
tinib 100 mg once daily was not associated
with any incidence of severe CHF or pericar-
dial  effusion  in  any  patient;  both  AEs  were
reported in patients receiving the 70 mg twice
daily dose (all grades, 4%; grade 3-4, 3%).
17
Both pericardial effusions and cardiac fail-
ure associated with dasatinib therapy may be
caused by similar mechanisms to those asso-
ciated with imatinib treatment, although, in
contrast with imatinib, dasatinib has not been
found  to  significantly  affect  mitochondrial
membrane potential, apoptosis, cell viability,
or cellular ultrastructure at physiological con-
Table 1. Reported incidence of cardiotoxicity during tyrosine kinase inhibitors treatment.
Toxicity n Incidence (%) Reference
Imatinib
Pericardial effusions NR 6 Novartis
20
Systolic heart failure 1276 1.8 Atallah et al
23
Congestive heart failure 553 0.7 Novartis
20
Left ventricular dysfunction 553 0.7 Novartis
20
Cardiac failure NR 0.1-1.0 Novartis
20
Flushing NR 0.1-1.0 Novartis
20
Hypertension NR 0.1-1.0 Novartis
20
Hypotension NR 0.1-1.0 Novartis
20
Peripheral coldness NR 0.1-1.0 Novartis
20
Tachycardia NR 0.1-1.0 Novartis
20
Pericarditis NR <0.1 Novartis
20
Dasatinib
Severe pericardial effusions NR 1 BMS
13
Congestive heart failure 911 4 Brave et al.
34
Arrhythmia NR 1-<10 BMS
13
Palpitations NR 1-<10 BMS
13
QT prolongation > 500 ms -300 <1 BMS
13
Angina pectoris NR 0.1-<1 BMS
13
Cardiomegaly NR 0.1-<1 BMS
13
Myocardial infarction NR 0.1-<1 BMS
13
Pericarditis NR 0.1-<1 BMS
13
Ventricular arrhythmia NR 0.1-<1 BMS
13
Acute coronary syndrome NR <0.1 BMS
13
Myocarditis NR <0.1 BMS
13
Nilotinib
Myocardial ischemia 321 7 Kantarjian et al.
31
Increase in QTcF >60 ms from BL 232 2.1 Novartis
18
Palpitations NR 1-10 Novartis
18
Angina pectoris NR 0.1-1 Novartis
18
Atrial fibrillation NR 0.1-1 Novartis
18
Bradycardia NR 0.1-1 Novartis
18
Cardiac failure NR 0.1-1 Novartis
18
Cardiac murmur NR 0.1-1 Novartis
18
Cardiomegaly NR 0.1-1 Novartis
18
Coronary artery disease NR 0.1-1 Novartis
18
Pericardial effusion NR 0.1-1 Novartis
18
Death
a 867 0.6 Novartis
18
BL, baseline; NR, not reported, representing all patients within each agent’s clinical trials. 
aPossibly resulting from ventricular repolarization.Article
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centrations.
27
Uncommon  cardiac  AEs  associated  with
dasatinib  include  angina  pectoris,  car-
diomegaly,  pericarditis,  ventricular  arrhyth-
mia,  and  myocardial  infarction  (reported  in
0.1 – <1% of patients). Rare events (reported
in <0.1% of patients) include myocarditis and
acute coronary syndrome.
13
Dasatinib should be administered with cau-
tion to any patient at risk of cardiac problems
(especially prolongation of the QT interval).
Patients with pre-existing congenital long QT
syndrome or those receiving anti-arrhythmic
medicine  should  be  monitored  closely.
13
Patients  with  hypokalemia  or  hypomagne-
semia should have these conditions corrected
prior to receiving dasatinib. As several anti-
neoplastic  agents,  including  the  anthracy-
clines, are associated with cardiotoxicity, the
treatment history of a patient should also be
taken into consideration before commencing
any therapy. Fluid retention events can typi-
cally  be  managed  by  supportive  measures.
Dose interruption is also indicated (Table 2).
13 
Conclusions
Although rare, severe CHF and left ventricu-
lar  dysfunction  have  occurred  with  imatinib
treatment,  especially  in  patients  receiving
higher doses. Cardiac failure is also an uncom-
mon feature of nilotinib and dasatinib therapy.
However,  CHF  has  not  yet  been  reported  in
patients with CP CML receiving dasatinib with
a starting dose of 100 mg once daily. Compared
with imatinib, palpitations and prolongation of
the  QT  interval  are  relatively  common  with
both dasatinib and nilotinib. Nilotinib carries a
black  box  warning  for  such  AE  and  sudden
death has been observed. These AEs may be
related to BCR-ABL inhibition and therefore be
genuine  class  effects.  Further  research  is
needed to clarify the mechanisms underlying
these effects.
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